{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004231","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.436761+00:00","generated_at":"2026-06-20T18:03:59.603760+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Mirum reports $76M total rev in 2022; LIVMARLI net sales $74M; CFO Clements to step down","bullets":["Total revenue $76M, LIVMARLI net product sales $74M for full year 2022 (preliminary unaudited).","Q4 2022 product sales $27M including $5M international partner orders.","CFO Ian Clements to step down effective May 15, 2023; will serve as consultant for 12 months.","sNDA for LIVMARLI in PFIC on track for Q1 2023; multiple pipeline catalysts in 2023.","Cash and investments ~$252M as of Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004231","json":"https://secwatch.observer/filing/0001193125-23-004231.json","markdown":"https://secwatch.observer/filing/0001193125-23-004231.md","text":"https://secwatch.observer/filing/0001193125-23-004231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523004231/0001193125-23-004231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523004231/d380757d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:03:59.603760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bacc0a247cf2f02ea9756628329084d577275d96","claim":"Mirum Pharmaceuticals, Inc. reported 2022 results: revenue $76 million total revenue.","evidence_excerpt":"$76 million in total revenue and $74 million net product sales anticipated for LIVMARLI for 2022, preliminary and unaudited","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523004231/0001193125-23-004231-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2022"},{"label":"Revenue","value":"$76 million total revenue"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"c86a03565dd7d71dc9a87544da2b401c03e5966d","claim":"Mirum Pharmaceuticals, Inc. reported Fourth quarter 2022 results: revenue $27 million estimated product sales.","evidence_excerpt":"Fourth quarter 2022 estimated product sales of $27 million includes an estimated $5 million of international sales through partner market supply orders, including inventory;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523004231/0001193125-23-004231-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth quarter 2022"},{"label":"Revenue","value":"$27 million estimated product sales"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"2b59f273b5","claim":"Ian Clements departed as Chief Financial Officer at Mirum Pharmaceuticals, Inc..","evidence_excerpt":"Dr. Clements will resign as Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523004231/0001193125-23-004231-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resign"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}